# BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

> **NCT03474770** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 16 (estimated)

## Conditions studied

- Focal Impaired Awareness Seizures

## Interventions

- **DRUG:** BIS-001ER

## Key facts

- **NCT ID:** NCT03474770
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-10
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2022-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474770, "BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03474770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*